Top

Published in:

01-01-2016 | Commentary

Defining cancer-related fatigue for biomarker discovery

Authors: Kristin Filler, Leorey N. Saligan

Published in: Supportive Care in Cancer | Issue 1/2016

Excerpt

Cancer-related fatigue (CRF) is a prominent and distressing symptom for cancer patients that can impair their overall health-related quality of life [1]. CRF is often described as a complex and multidimensional concept consisting of physical, cognitive, affective, spiritual, psychosocial, and environmental factors [1, 2]. Assessment of CRF is obtained from responses on various valid, self-report questionnaires established from several theoretical models of CRF. The complexity of CRF as a concept and the variability in the method of CRF assessment pose a challenge to investigators attempting to understand the etiology of CRF. Establishing a clear definition of a phenomenon, such as CRF, is an essential starting point for phenotypic characterization and biomarker discovery [3]. Therefore, this commentary aims to increase our awareness of the need for better definition and clearer phenotypic characterization of CRF. …

Bower JE (2007) Cancer-related fatigue: links with inflammation in cancer patients and survivors. Brain Behav Immun 21:863–871. doi:10.1016/j.bbi.2007.03.013 PubMedCentralCrossRefPubMed

Kwak SM, Choi YS, Yoon HM, et al (2012) The relationship between interleukin-6, tumor necrosis factor-α, and fatigue in terminally ill cancer patients. Palliat Med 26:275–282. doi:10.1177/0269216311406991 CrossRefPubMed

Mischak H, Allmaier G, Apweiler R, et al (2010) Recommendations for biomarker identification and qualification in clinical proteomics. Sci Transl Med 2:46 ps42. doi:10.1126/scitranslmed.3001249 CrossRef

Bower JE, Bak K, Berger A, et al (2014) Screening, assessment, and management of fatigue in adult survivors of cancer: an American society of clinical oncology clinical practice guideline adaptation. J Clin Oncol 32:1840–1850. doi:10.1200/JCO.2013.53.4495 PubMedCentralCrossRefPubMed

Howell D, Keshavarz H, Broadfield L, et al. A pan canadian practice guideline for screening, assessment, and management of cancer-related fatigue in adults: Version 2–2015. Toronto: Canadian Partnership Against Cancer (Cancer Journey Advisory Group) and the Canadian Association of Psychosocial Oncology, April 2015. Retrieved from http://www.capo.ca/pdf/CRF_Guideline.pdf

Saligan LN, Olson K, Filler K, et al (2015) The biology of cancer-related fatigue: a review of the literature. Support Care Cancer 23:2461–2478. doi:10.1007/s00520-015-2763-0 CrossRefPubMed

Alexander S, Minton O, Andrews P, Stone P (2009) A comparison of the characteristics of disease-free breast cancer survivors with or without cancer-related fatigue syndrome. Eur J Cancer 45:384–392. doi:10.1016/j.ejca.2008.09.010 PubMedCentralCrossRefPubMed

Massacesi C, Terrazzino S, Marcucci F, et al (2006) Uridine diphosphate glucuronosyltransferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy. Cancer 106:1007–1016. doi:10.1002/cncr.21722 CrossRefPubMed

Cashion A, Grady P (2015) The national institutes of health/national institutes of nursing research intramural research program and the development of the national institutes of health symptom science model. Nurs Outlook 63:484–487. doi:10.1016/j.outlook.2015.03.001 CrossRefPubMed

10.

Wratten C, Kilmurray J, Nash S, Seldon M, Hamilton CS, O’Brien PC, Denham JW (2004) Fatigue during breast radiotherapy and its relationship to biological factors. Int J Radiat Oncol Biol Phys 59:160–167. doi:10.1016/j.ijrobp.2003.10.008 CrossRefPubMed

11.

Courtier N, Gambling T, Enright S, Barrett-Lee P, Abraham J, Mason MD (2013) Psychological and immunological characteristics of fatigued women undergoing radiotherapy for early-stage breast cancer. Support Care Cancer 21:173–181. doi:10.1007/s00520-012-1508-6 CrossRefPubMed

12.

Cheville A (2009) Cancer-related fatigue. Phys Med Rehabil Clin N Am 20:405–416. doi:10.1016/j.pmr.2008.12.005 CrossRefPubMed

13.

Wood LJ, Nail LM, Perrin NA, Elsea CR, Fischer A, Druker BJ (2006) The cancer chemotherapy drug etoposide (VP-16) induces proinflammatory cytokine production and sickness behavior-like symptoms in a mouse model of cancer chemotherapy-related symptoms. Biol Res Nurs 8:57–169. doi:10.1177/1099800406290932 CrossRef

14.

Tezal M, Scannapieco FA, Wactawski-Wende J, Hyland A, Marshall JR, Rigual NR, Stoler DL (2012) Local inflammation and human papillomavirus status of head and neck cancers. Arch Otolaryngol Head Neck Surg 138:669–675. doi:10.1001/archoto.2012.873 PubMedCentralCrossRefPubMed

15.

Marquette C, Linard C, Galonnier M, Van Uye A, Mathieu J, Gourmelon P, Clarençon D (2003) IL-1beta, TNFalpha and IL-6 induction in the rat brain after partial-body irradiation: role of vagal afferents. Int J Radiat Biol 79:777–785. doi:10.1080/09553000310001610998 CrossRefPubMed

16.

Seigers R, Schagen SB, Van Tellingen O, Dietrich J (2013) Chemotherapy-related cognitive dysfunction: current animal studies and future directions. Brain Imaging Behav 7:453–459. doi:10.1007/s11682-013-9250-3 CrossRefPubMed

17.

Bower JE, Lamkin DM (2013) Inflammation and cancer-related fatigue: mechanisms, contributing factors, and treatment implications. Brain Behav Immun 30:S48–S57. doi:10.1016/j.bbi.2012.06.011 PubMedCentralCrossRefPubMed

18.

Ganz PA, Bower JE (2007) Cancer related fatigue: a focus on breast cancer and Hodgkin’s disease survivors. Acta Oncol 46:474–479. doi:10.1080/02841860701367845 CrossRefPubMed

19.

Lutgendorf SK, Weinrib AZ, Penedo F, et al (2008) Interleukin-6, cortisol, and depressive symptoms in ovarian cancer patients. J Clin Oncol 26:4820–4827. doi:10.1200/JCO.2007.14.1978 PubMedCentralCrossRefPubMed

20.

Raison CL, Capuron L, Miller AH (2006) Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 27:24–31. doi:10.1016/j.it.2005.11.006 PubMedCentralCrossRefPubMed

Title: Defining cancer-related fatigue for biomarker discovery
Authors: Kristin Filler
Leorey N. Saligan
Publication date: 01-01-2016
Publisher: Springer Berlin Heidelberg
Published in: Supportive Care in Cancer / Issue 1/2016
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-015-2965-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2016

Cancer’s positive flip side: posttraumatic growth after childhood cancer

Towards a better understanding of the relationship between side effects of analgesia and quality of life in patients with multiple myeloma

Serum-derived bovine immunoglobulin/protein isolate in the alleviation of chemotherapy-induced mucositis

Interval versus continuous aerobic exercise training in breast cancer survivors—a pilot RCT

Incidence of bone pain in patients with breast cancer treated with lipegfilgrastim or pegfilgrastim: an integrated analysis from phase II and III studies

Sexual activity and function after surgical treatment in patients with (pre)invasive vulvar lesions

Keynote webinar | Spotlight on antibody–drug conjugates in cancer